Home / Therapies / SGLT-2 Therapy Center

SGLT-2 Therapy Center

Diabetes in Control is pleased to provide you with the latest insights and information on the Sodium-Dependent Glucose Transporter Two (SGLT-2) drug class to help optimize your practice. We hope you’ll benefit from the insights and share them with your colleagues. Thanks for all you’re doing to improve your patients’ lives and longevity!

Dapagliflozin a Potential Treatment for Type 1 Patients

Apr 28, 2020 Type 1 Diabetes, SGLT-2 Therapy Center

The future could hold more treatment options for patients with type 1 diabetes.

Empagliflozin Produces Liver Fat Reduction in Randomized Control Trial

Mar 21, 2020 Type 2 Diabetes, SGLT-2 Therapy Center

Could empagliflozin contribute to the early treatment of NAFLD in patients with T2DM?

CREDENCE Trial – Overlooked Benefits In Preventing CVD

Mar 3, 2020 Cardiology, SGLT-2 Therapy Center

SGLT2 Inhibitors and their use for preventing cardiovascular diseases.

Canagliflozin for Those on Triple Drug Therapy with Uncontrolled Diabetes

Feb 29, 2020 Paid, SGLT-2 Therapy Center

SGLT-2 inhibitors have proved to be successful hypoglycemics, so should they be recommended earlier for those not achieving goal A1c reductions?

SGLT-2 Inhibitors: Teach from the Start and Manage Expectations

Feb 4, 2020 Disasters Averted, SGLT-2 Therapy Center

A female patient, 42 years of age, with type 2 diabetes, is overweight with a history of vaginal yeast infections with elevated glucose levels. Wanting to better manage her diabetes and lose some weight, the commercials about SGLT-2 inhibitors caught her attention.

FDA Approves a Triple Therapy for Type 2 Diabetes in One Tablet

Feb 4, 2020 Type 2 Diabetes, Paid, DPP-4 Therapy Center, Metformin Therapy Center, SGLT-2 Therapy Center

More may be better unless it involves tablets. A newly approved, more straightforward way to treat type 2 diabetes.

SGLT-2i Effects on Major Cardiovascular Events and Heart Failure

Jan 11, 2020 Cardiology, SGLT-2 Therapy Center

The use of SGLT2 inhibitors was associated with reduced risk of any cause of death in patients with or without a history of major cardiovascular disease.